Evidence map›Paper›PMID 35229869›Full record

ReviewAlcohol and alcoholism (Oxford, Oxfordshire)2022

A Meta-Regression of Trial Features Predicting the Effects of Alcohol Use Disorder Pharmacotherapies on Drinking Outcomes in Randomized Clinical Trials: A Secondary Data Analysis.

Erica N Grodin, Suzanna Donato, Han Du, ReJoyce Green, Spencer Bujarski, Lara A Ray

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Alcohol and alcoholism (Oxford, Oxfordshire), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Erica N GrodinDepartment of Psychology, University of California, 502 Portola Plaza, Los Angeles, California 90095 USA.ORCID 0000-0001-5528-4918
Suzanna DonatoDepartment of Psychology, University of California, 502 Portola Plaza, Los Angeles, California 90095 USA.
Han DuDepartment of Psychology, University of California, 502 Portola Plaza, Los Angeles, California 90095 USA.
ReJoyce GreenDepartment of Psychology, University of California, 502 Portola Plaza, Los Angeles, California 90095 USA.
Spencer BujarskiDepartment of Psychology, University of California, 502 Portola Plaza, Los Angeles, California 90095 USA.
Lara A RayDepartment of Psychology, University of California, 502 Portola Plaza, Los Angeles, California 90095 USA.
University of California, Los Angeles · US

Funding

UCLA Training Program in Translational Neuroscience of Drug Abuse (TNDA)T32DA024635 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LARA A. RAY, Kate M Wassum · 2008 to 2026
$6.2M
Clinical Neuroscience of Alcoholism: Integrating Neuroscience and Clinical TrialsK24AA025704 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LARA A. RAY · 2018 to 2026
$1.3M
NIAAA NIH HHS K24 AA025704NIAAA NIH HHS K24AA025704NIDA NIH HHS T32 DA024635NIDA NIH HHS T32DA024635
6 · The paper itself

Abstract

aimsTo test whether two critical design features, inclusion criteria of required pre-trial abstinence and pre-trial alcohol use disorder (AUD) diagnosis, predict the likelihood of detecting treatment effects in AUD pharmacotherapy trials.

methodsThis secondary data analysis used data collected from a literature review to identify randomized controlled pharmacotherapy trials for AUD. Treatment outcomes were selected into abstinence and no heavy drinking. Target effect sizes were calculated for each outcome and a meta-regression was conducted to test the effects of required pre-trial abstinence, required pre-trial AUD diagnosis, and their interaction on effect sizes. A sub-analysis was conducted on trials, which included FDA-approved medications for AUD.

resultsIn total, 118 studies testing 19 medications representing 21,032 treated participants were included in the meta-regression analysis. There was no significant effect of either predictor on abstinence or no heavy drinking outcomes in the full analysis or in the sub-study of FDA-approved medications.

conclusionBy examining these design features in a quantitative, rather than qualitative, fashion the present study advances the literature and shows that requiring AUD diagnosis or requiring pre-trial abstinence do not impact the likelihood of a significant medication effect in the trial.

Indexed as

AlcoholismAlcohol DrinkingData AnalysisHumansTreatment Outcome

Identifiers

PMID35229869
PMCPMC9465523
OpenAlexW4214602086

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.